专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110070207A1 THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS 审中-公开
标题翻译：治疗组合物
公开(公告)号：US20110070207A1
公开(公告)日：2011-03-24
申请号：US12951612
申请日：2010-11-22
申请人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
发明人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
IPC分类号： A61K35/28 , A61K35/12 , A61P17/00
CPC分类号： C12N5/0663 , A61K2035/124
摘要： A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.
摘要翻译：公开了一种新型治疗剂，人类间充质干细胞，以及含有它们用于治疗特应性皮炎的组合物。还公开了一种治疗患者特应性皮炎的方法。

2. 发明申请

US20090246181A1 THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS 审中-公开
标题翻译：治疗组合物
公开(公告)号：US20090246181A1
公开(公告)日：2009-10-01
申请号：US12412598
申请日：2009-03-27
申请人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
发明人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
IPC分类号： A61K35/28 , C12N5/08 , A61P17/00
CPC分类号： C12N5/0663 , A61K2035/124
摘要： A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.
摘要翻译：公开了一种新型治疗剂，人类间充质干细胞，以及含有它们用于治疗特应性皮炎的组合物。还公开了一种治疗患者特应性皮炎的方法。

3. 发明申请

US20130172400A1 CANCER CELL IDENTIFICATION MARKER AND CANCER CELL PROLIFERATION INHIBITOR 有权
标题翻译：癌细胞鉴定标记和癌细胞增殖抑制剂
公开(公告)号：US20130172400A1
公开(公告)日：2013-07-04
申请号：US13613626
申请日：2012-09-13
申请人： Masahiko KURODA , Masakatsu Takanashi , Kosuke Oikawa
发明人： Masahiko KURODA , Masakatsu Takanashi , Kosuke Oikawa
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011 , G01N33/57496
摘要： Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ.
摘要翻译：公开了可用于检测各种人类癌细胞并且其表达与细胞的恶性改变密切相关的鉴定标记物，以及基于通过抑制识别标志物表达抑制癌细胞增殖的人类癌症治疗用组合物。该标记物是人异染色质蛋白质1gamma（HP1gamma），并且用于癌症治疗的组合物包含一种或多种抑制人HP1gamma基因（例如人HP1gamma的siRNA）表达的试剂。

4. 发明申请

US20130012412A1 MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT 审中-公开
标题翻译：乳腺癌诊断标记，测试方法和测试包
公开(公告)号：US20130012412A1
公开(公告)日：2013-01-10
申请号：US13618415
申请日：2012-09-14
申请人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI
发明人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI
IPC分类号： C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178
摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.
摘要翻译：本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为简单，可靠性高。与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

5. 发明申请

US20140170648A1 CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT 有权
标题翻译：癌症标记，使用癌症标记评估癌症的方法和评估试剂
公开(公告)号：US20140170648A1
公开(公告)日：2014-06-19
申请号：US14039835
申请日：2013-09-27
申请人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
发明人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

6. 发明申请

US20120270746A1 CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT 有权
标题翻译：癌症标记，使用癌症标记评估癌症的方法和评估试剂
公开(公告)号：US20120270746A1
公开(公告)日：2012-10-25
申请号：US13472190
申请日：2012-05-15
申请人： Masahiko KURODA , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
发明人： Masahiko KURODA , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
IPC分类号： C12Q1/68 , G01N21/64 , C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

7. 发明申请

US20150315653A9 METHOD FOR INHIBITING SIGNALING MEDIATED BY ERBB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF 审中-公开
标题翻译：用于抑制ERBB2介导的信号传导的方法，用于其的信号抑制剂及其用途
公开(公告)号：US20150315653A9
公开(公告)日：2015-11-05
申请号：US12563241
申请日：2009-09-21
申请人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
发明人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
IPC分类号： C12Q1/68 , C07H21/00 , C12N15/63 , C07K16/00 , A61P35/00 , C12Q1/02 , C12N5/071 , C07K14/00
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K38/1709 , A61K39/39558 , A61K48/00 , C07K14/4703 , C07K16/32 , C07K2317/24 , C07K2319/02 , C12N9/1205 , C12Q2600/158 , G01N33/5011 , G01N33/5041 , G01N33/57407 , G01N33/57484 , G01N33/57492 , G01N2333/71 , A61K2300/00
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供一种抑制人细胞中ErbB2介导的信号传导途径的活化和用于其的信号传导抑制剂的方法。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。上述多肽可以直接引入细胞，或者可以将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于ErbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

8. 发明申请

US20140178874A1 METHOD FOR EVALUATING CANCER 审中-公开
标题翻译：癌症评估方法
公开(公告)号：US20140178874A1
公开(公告)日：2014-06-26
申请号：US14032651
申请日：2013-09-20
申请人： Masahiko KURODA , Akira SAITO , Maki SANO
发明人： Masahiko KURODA , Akira SAITO , Maki SANO
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.
摘要翻译：提供了一种使用新型癌症标志物评价受试者的癌症的发病，临床前期，临床阶段或预后的癌症评价方法。使用至少一种选自hsa-miR-92和hsa-miR-494的miRNA作为癌症评价中的新型癌症标志物。检测细胞或组织样品中的癌症标志物，并根据癌症标志物的表达水平评估样品中癌症的可能性。根据该评价方法，通过检测miRNA作为癌症标记物，可以以极好的可靠性来评价样品中癌症的可能性。作为检测癌症标记物的方法，优选使用例如相对于被固定化的样品的标记探针进行原位杂交法。

9. 发明申请

US20100144849A1 METHOD FOR INHIBITING SIGNALING MEDIATED BY ErbB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF 审中-公开
标题翻译：用于抑制由ErbB2介导的信号传导的方法，用于其的信号抑制剂及其用途
公开(公告)号：US20100144849A1
公开(公告)日：2010-06-10
申请号：US12563241
申请日：2009-09-21
申请人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
发明人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
IPC分类号： A61K31/7052 , C12N5/071 , C07H21/00 , C12N15/63 , C07K14/00 , C07K16/00 , A61P35/00 , C12Q1/02
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K38/1709 , A61K39/39558 , A61K48/00 , C07K14/4703 , C07K16/32 , C07K2317/24 , C07K2319/02 , C12N9/1205 , C12Q2600/158 , G01N33/5011 , G01N33/5041 , G01N33/57407 , G01N33/57484 , G01N33/57492 , G01N2333/71 , A61K2300/00
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供一种抑制人细胞中ErbB2介导的信号传导途径的激活和用于其的信号传导抑制剂的方法。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。上述多肽可以直接引入细胞，或者可以将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于ErbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式